EDSA (Edesa Biotech) Other Financing: $-0.18 Mil (TTM As of Mar. 2026)


EDSA Edesa Biotech Inc EDSA
26 GF Score
Price $7.45
! 2 Warning Signs
View Full Analysis

What is Edesa Biotech Other Financing?

Edesa Biotech EDSA -3.23% 26 Other Financing is $-0.18 Mil as of Mar. 2026. GuruFocus rates EDSA with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Edesa Biotech's Other Financing for the three months ended in Mar. 2026 was $0.00 Mil.

Edesa Biotech's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.18 Mil.

Edesa Biotech Other Financing Historical Data

* Premium members only.

The historical data trend for Edesa Biotech's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edesa Biotech Other Financing Chart

Edesa Biotech Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.51 -0.33 0.49 -0.11 -0.57

Edesa Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.44 0.00 -0.04 -0.14 0.00
EDSA
26GF Score
Edesa Biotech Inc EDSA
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edesa Biotech Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-0.18 Mil mean?
Edesa Biotech (EDSA) has a Other Financing of $-0.18 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Edesa Biotech and its competitors.
Is Edesa Biotech's Other Financing too high?
Edesa Biotech's current Other Financing is $-0.18 Mil. Overall, Edesa Biotech has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Edesa Biotech's Other Financing compare to ACET and HRTX?
Edesa Biotech's Other Financing of $-0.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Edesa Biotech and its competitors. Edesa Biotech's current Other Financing is $-0.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edesa Biotech stock overvalued right now?
Edesa Biotech (EDSA) has a current Other Financing of $-0.18 Mil. The current Other Financing is $-0.18 Mil. Edesa Biotech's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Edesa Biotech (EDSA), the current Other Financing is $-0.18 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Edesa Biotech Business Description

Address 100 Spy Court, Markham, ON, CAN, L3R 5H6
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
26GF Score

Get the complete analysis for EDSA

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.45
Price